https://www.nasdaq.com/press-release/antares-pharma-announces-divestiture-of-otrexupr-2021-12-15
https://www.nasdaq.com/press-release/antares-pharma-to-participate-in-the-piper-sandler-33rd-annual-virtual-healthcare
https://www.nasdaq.com/press-release/antares-pharma-to-present-at-the-jefferies-london-healthcare-conference-2021-11-10
https://www.nasdaq.com/press-release/antares-pharma-reports-third-quarter-2021-financial-and-operating-results-2021-11-04
https://www.nasdaq.com/press-release/antares-pharma-announces-appointment-of-carmen-volkart-to-its-board-of-directors-2021
https://www.nasdaq.com/press-release/antares-pharma-announces-oral-presentation-at-the-22nd-annual-fall-scientific-meeting
https://www.nasdaq.com/press-release/antares-pharma-to-report-third-quarter-2021-financial-and-operating-results-2021-10
https://www.nasdaq.com/press-release/antares-pharma-enters-into-exclusive-license-agreement-with-lipocine-for-tlandor-in-u
https://www.nasdaq.com/press-release/antares-pharma-initiates-phase-i-study-for-atrs-1902-for-adrenal-crisis-rescue-2021
https://www.nasdaq.com/press-release/antares-pharma-to-participate-in-the-h.c.-wainwright-23rd-annual-global-investment
https://www.nasdaq.com/press-release/antares-pharma-reports-second-quarter-2021-financial-and-operating-results-2021-08-05
https://www.nasdaq.com/press-release/antares-pharma-to-report-second-quarter-2021-financial-and-operating-results-2021-07
https://www.nasdaq.com/press-release/antares-pharma-announces-fda-acceptance-of-ind-application-for-atrs-1902-for-adrenal
https://www.nasdaq.com/press-release/antares-pharma-to-present-at-the-ladenburg-thalmann-annual-healthcare-conference-2021
https://www.nasdaq.com/press-release/antares-pharma-announces-partner-idorsia-initiates-the-phase-3-study-with-selatogrel
https://www.nasdaq.com/press-release/antares-pharma-announces-submission-of-ind-application-for-atrs-1902-for-adrenal
https://www.nasdaq.com/press-release/antares-pharma-to-present-at-the-raymond-james-human-health-innovations-conference
https://www.nasdaq.com/press-release/antares-pharma-to-present-at-the-jefferies-virtual-healthcare-conference-2021-05-26
https://www.nasdaq.com/press-release/antares-pharma-appoints-joseph-renda-as-senior-vice-president-of-commercial-2021-05
https://www.nasdaq.com/press-release/antares-pharma-reports-first-quarter-2021-financial-and-operating-results-2021-05-06
https://www.nasdaq.com/press-release/antares-pharma-announces-poster-presentation-at-the-pediatric-endocrine-society-2021
https://www.nasdaq.com/press-release/antares-pharma-to-participate-in-the-7th-annual-truist-securities-2021-life-sciences
https://www.nasdaq.com/press-release/antares-pharma-to-report-first-quarter-2021-financial-and-operating-results-2021-04
https://www.nasdaq.com/press-release/antares-pharma-appoints-dr.-peter-richardson-as-executive-vice-president-research-and
https://www.nasdaq.com/press-release/antares-pharma-reports-fourth-quarter-and-full-year-2020-financial-and-operating
https://www.nasdaq.com/press-release/antares-pharma-to-present-at-two-upcoming-investor-conferences-2021-02-24
https://www.nasdaq.com/press-release/antares-pharma-to-report-fourth-quarter-and-full-year-2020-financial-and-operating
https://www.nasdaq.com/press-release/antares-pharma-to-participate-in-the-svb-leerink-10th-annual-virtual-global
https://www.nasdaq.com/press-release/antares-pharma-announces-full-year-2021-revenue-guidance-of-%24175-200-million-2021-01
https://www.nasdaq.com/press-release/antares-pharma-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare
https://www.nasdaq.com/press-release/antares-pharma-to-present-at-the-jefferies-virtual-london-healthcare-conference-2020
https://www.nasdaq.com/press-release/antares-pharma-reports-strong-third-quarter-2020-financial-and-operating-results-2020
https://www.nasdaq.com/press-release/antares-pharma-to-report-third-quarter-2020-financial-and-operating-results-2020-10
https://www.nasdaq.com/press-release/antares-pharma-enters-exclusive-license-agreement-with-ferring-pharmaceuticals-for
https://www.nasdaq.com/press-release/antares-pharma-to-present-at-the-h.c.-wainwright-22nd-annual-global-virtual
https://www.nasdaq.com/press-release/antares-pharma-appoints-tram-bui-as-vice-president-of-corporate-communications-and
https://www.nasdaq.com/press-release/antares-pharma-reports-strong-second-quarter-2020-operating-and-financial-results
https://www.nasdaq.com/press-release/antares-pharma-and-lunatus-enter-into-an-exclusive-distribution-agreement-for
https://www.nasdaq.com/press-release/antares-pharma-to-report-second-quarter-2020-operating-and-financial-results-2020-07
https://www.nasdaq.com/press-release/first-commercial-product-using-antares-pharmas-multi-dose-pen-platform-launches-in
https://www.nasdaq.com/press-release/antares-pharma-appoints-patrick-shea-senior-vice-president-of-commercial-2020-07-20
https://www.nasdaq.com/press-release/antares-pharma-to-present-at-the-raymond-james-human-health-innovation-conference
https://www.nasdaq.com/press-release/antares-pharma-to-present-at-the-jefferies-virtual-healthcare-conference-2020-05-27
https://www.nasdaq.com/press-release/antares-pharma-reports-first-quarter-2020-operating-and-financial-results-2020-05-05
https://www.nasdaq.com/press-release/antares-pharma-to-report-first-quarter-2020-operating-and-financial-results-2020-04
https://www.nasdaq.com/press-release/antares-pharma-reports-fourth-quarter-and-full-year-2019-operating-and-financial
https://www.nasdaq.com/press-release/antares-pharma-to-present-at-the-cowen-and-company-40th-annual-health-care-conference
https://www.nasdaq.com/press-release/antares-pharma-to-report-fourth-quarter-and-full-year-2019-financial-and-operating
https://www.nasdaq.com/press-release/antares-pharma-announces-full-year-2020-net-revenue-guidance-range-of-%24135-to-%24155
https://www.nasdaq.com/press-release/antares-pharma-appoints-edward-tykot-senior-vice-president-corporate-development-2019
https://www.nasdaq.com/press-release/antares-pharma-social-media-campaign-for-xyostedr-wins-marcom-platinum-award-2019-12
https://www.nasdaq.com/press-release/antares-pharma-to-present-at-the-31st-annual-piper-jaffray-healthcare-conference-2019
https://www.nasdaq.com/press-release/reminder%3a-antares-pharma-enters-into-a-global-development-agreement-with-idorsia
https://www.nasdaq.com/press-release/antares-pharma-enters-into-a-global-development-agreement-with-idorsia
https://www.nasdaq.com/press-release/antares-pharma-to-present-at-the-jefferies-2019-london-healthcare-conference-2019-11
https://www.nasdaq.com/press-release/antares-pharma-reports-third-quarter-2019-operating-and-financial-results-2019-11-05
https://www.nasdaq.com/press-release/antares-pharma-announces-receipt-of-final-payment-from-sale-of-zomajettm-needle-free
https://www.nasdaq.com/press-release/antares-pharma-to-report-third-quarter-2019-financial-and-operating-results-2019-10
https://www.nasdaq.com/press-release/antares-pharma-announces-two-poster-presentations-at-the-2019-sexual-medicine-society
https://www.nasdaq.com/press-release/antares-pharma-to-present-at-the-ladenburg-thalmann-2019-healthcare-conference-2019
